VUNO said VUNO Med-DeepCARS, designed to predict cardiac arrest, has achieved a record-breaking number of new contracts and an increase in bed allocations on a monthly basis since its introduction to the market.

Throughout January, VUNO has successfully forged agreements with more than 10 healthcare facilities, including two tertiary general hospitals, securing in excess of 3,500 new billing beds.

This marks a notable expansion for VUNO Med-DeepCARS.

As of the end of January, VUNO Med-DeepCARS has been implemented in over 70 hospitals, including 13 tertiary general hospitals. In addition, around 40 other hospitals are in various stages of demonstration and purchasing processes.

VUNO Med-DeepCARS stands out as the first of its kind in Korea's medical AI sector to be acknowledged as an advanced medical technology by the National Evidence-based Healthcare Collaborating Agency (NECA).

The device operates by analyzing patients' vital signs, such as respiration, blood pressure, pulse, and temperature, in general wards to anticipate cardiac arrest occurrences within a 24-hour window.

The company stressed that the solution's implementation has been rapid, primarily due to its billing model, which is based on actual daily usage per bed, contributing to VUNO's revenue growth.

The increase in marginal profits from VUNO Med-DeepCARS is also seen as a positive indicator of VUNO achieving its break-even point (BEP) in the upcoming quarters.

"VUNO Med-DeepCARS has begun the year on a strong note, securing contracts with more than ten hospitals and a substantial number of medical institutions transitioning to our billing model," VUNO's Business Managing Director Lim Seok-hun said. "The product, being offered as a Software as a Service (SaaS), is not only bolstering our ongoing revenue streams but also contributing to the continuous improvement in our prospects of achieving our targeted quarterly profitability."

Meanwhile, VUNO Med-DeepCARS is set to expand into the U.S. market by the end of this year.

The product was previously recognized as a breakthrough medical device by the U.S. FDA and FDA approval is targeted for the latter half of this year.

Parallel to these efforts, VUNO is engaged in clinical research with medical institutions in the U.S. and has completed the patent registrations for its key technological innovations.